Premium Nahrungsergänzungsmittel | artgerecht

Secondary Hyperaldosteronism – Causes and Treatment

Secondary hyperaldosteronism is a condition in which the body produces too much aldosterone, triggered by an external cause such as kidney disease or heart failure.

Regular tips about health Regular tips about health

Things worth knowing about "Secondary Hyperaldosteronism"

Secondary hyperaldosteronism is a condition in which the body produces too much aldosterone, triggered by an external cause such as kidney disease or heart failure.

What is Secondary Hyperaldosteronism?

Secondary hyperaldosteronism is a disorder in which the adrenal cortex produces excessive amounts of the hormone aldosterone. Unlike primary hyperaldosteronism, the underlying cause does not originate within the adrenal gland itself but rather externally – most commonly through dysregulation of the renin-angiotensin-aldosterone system (RAAS). This system regulates blood pressure and the body´s salt and water balance.

Causes

Secondary hyperaldosteronism develops due to elevated renin secretion from the kidneys, which in turn stimulates aldosterone production. Common triggers include:

Heart failure: The heart pumps insufficient blood, causing the kidneys to perceive a low blood pressure and activate the RAAS.
Liver cirrhosis: Chronic liver disease leading to fluid accumulation and altered hormonal regulation.
Nephrotic syndrome: A kidney disorder characterized by excess protein loss in the urine and reduced blood volume.
Renovascular hypertension: Narrowing of the renal arteries (e.g., due to atherosclerosis), prompting the kidneys to release increased amounts of renin.
Chronic volume depletion: For example, from prolonged diuretic use, persistent diarrhea, or severe vomiting.
Pregnancy: Physiologically elevated aldosterone levels during pregnancy may be further increased in some conditions.

Symptoms

Symptoms of secondary hyperaldosteronism arise from the effects of excess aldosterone on the body´s mineral balance:

High blood pressure (hypertension): A frequent and central symptom.
Hypokalemia: Low blood potassium levels, which can lead to muscle weakness, fatigue, cramps, and cardiac arrhythmias.
Edema: Fluid retention in tissues, particularly in the legs and ankles.
Polyuria and polydipsia: Increased urination and excessive thirst.
General weakness and fatigue.

Diagnosis

Diagnosing secondary hyperaldosteronism requires a combination of laboratory tests and imaging studies:

Blood tests: Measurement of aldosterone and renin levels in the blood. In secondary hyperaldosteronism, both values are elevated (in contrast to primary hyperaldosteronism, where renin is suppressed).
Aldosterone-to-renin ratio (ARR): The ratio of these two hormones helps differentiate between primary and secondary hyperaldosteronism.
Electrolyte panel: Detection of low potassium levels (hypokalemia).
Imaging: Ultrasound, CT, or MRI to evaluate the kidneys, adrenal glands, liver, and heart in order to identify the underlying cause.
Urine analysis: Measurement of aldosterone excretion in a 24-hour urine collection.

Treatment

Treatment of secondary hyperaldosteronism is primarily directed at the underlying cause:

Treatment of the Underlying Condition

When the triggering disease – such as heart failure, liver cirrhosis, or renal artery stenosis – is successfully managed, aldosterone overproduction often normalizes as well.

Pharmacological Therapy

Aldosterone antagonists (e.g., spironolactone, eplerenone): Block the effects of aldosterone at its receptors, lowering blood pressure and reducing potassium loss.
ACE inhibitors or AT1 receptor blockers (ARBs): These medications interfere with the RAAS and help reduce aldosterone production.
Potassium supplementation: Administered when potassium levels are significantly low.

Interventional or Surgical Approaches

In cases of renovascular hypertension caused by renal artery stenosis, balloon dilation (angioplasty) or surgical repair of the narrowed artery may be considered.

References

Funder JW et al. - The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2016.
Williams GH - Aldosterone biosynthesis, regulation, and classical mechanism of action. Heart Failure Reviews, 2005.
Young WF - Primary aldosteronism: renaissance of a syndrome. Clinical Endocrinology, 2007.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.